SCHEMBL7105979

SCHEMBL7105979

N[C@@H](CC(=O)O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
GRM8 O00222 1/20 0.48
GRM6 O15303 1/20 0.48
GRM4 Q14833 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
TSHR P16473 1/20 0.46
NPC1 O15118 1/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
CES1 P23141 2/20 0.44
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
CES2 O00748 1/20 0.43
SRD5A2 P31213 1/20 0.43
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
MMP2 P08253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5720945 1.00 ALDH1A1 (0.49) ALDH1A1GRM8GRM6GRM4TDP1
SCHEMBL2452348 1.00 ALDH1A1 (0.49) ALDH1A1GRM8GRM6GRM4TDP1
SCHEMBL6474872 0.84 KMT2A (0.56) ALDH1A1TDP1KMT2AMEN1NPC1
SCHEMBL1857061 0.82 FNTA (0.58) ALDH1A1TDP1KMT2AMEN1TSHR
SCHEMBL3859569 0.81 KMO (0.55) GRM8GRM6GRM4KMT2AMEN1
SCHEMBL666885 0.81 KMO (0.55) GRM8GRM6GRM4KMT2AMEN1
SCHEMBL19833069 0.81 NPC1 (0.48) ALDH1A1GRM8GRM6GRM4TDP1
SCHEMBL4833185 0.81 NPC1 (0.48) ALDH1A1KMT2AMEN1NPC1MAPT
SCHEMBL18133735 0.81 NPC1 (0.48) ALDH1A1GRM8GRM6GRM4TDP1
SCHEMBL3310878 0.81 KMO (0.55) GRM8GRM6GRM4KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162799-A1 Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents CELLTECH R&D LIMITED (GB) 2003-08-28 US disclosed
US-6518283-B1 To modify integrin function in such a way as to beneficially modulate cell adhesion CELLTECH R&D LIMITED (GB) 2003-02-11 US disclosed
EP-1181266-A1 SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES Celltech R&D Limited (GB) 2002-02-27 EP disclosed
WO-2000073260-A1 SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES CELLTECH R&D LIMITED (GB) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162799-A1 Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents ICAM1, VCAM1, CCR1 ALDH1A1 287/4885GRM8 3152/4885GRM6 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.